Literature DB >> 10619624

Cimetidine treatment for recurrent respiratory papillomatosis.

J P Harcourt1, G Worley, S E Leighton.   

Abstract

Effective adjuvant treatment for recurrent respiratory papillomatosis (RRP) is at present limited to alpha-interferon, which may have significant side effects including rebound growth of papillomata following its withdrawal, is given by injection and is expensive. High dose cimetidine is known to have immunomodulatory side effects and has been reported as a useful treatment for cutaneous warts. We report a case of very advanced RRP with tracheo-bronchial-pulmonary involvement treated with adjuvant cimetidine at a dose of 40 mg/kg for 4 months. The patient enjoyed a remarkable improvement in her clinical condition following treatment. The literature regarding cimetidine treatment for cutaneous warts is reviewed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619624     DOI: 10.1016/s0165-5876(99)00279-7

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  9 in total

Review 1.  [Current therapeutic options for recurrent respiratory papillomatosis].

Authors:  K Huber; H Sadick; K Götte
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

Review 2.  Recurrent respiratory papillomatosis.

Authors:  R A Tasca; R W Clarke
Journal:  Arch Dis Child       Date:  2006-08       Impact factor: 3.791

Review 3.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 4.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

Review 5.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

Review 6.  Recurrent respiratory papillomatosis: current and future perspectives.

Authors:  Marco Carifi; Domenico Napolitano; Morando Morandi; Danilo Dall'Olio
Journal:  Ther Clin Risk Manag       Date:  2015-05-05       Impact factor: 2.423

7.  No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.

Authors:  Moshe Rogosnitzky; Esther Berkowitz; Alejandro R Jadad
Journal:  JMIRx Med       Date:  2020-09-30

8.  Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects.

Authors:  Dihia Meghnem; Sharon A Oldford; Ian D Haidl; Lisa Barrett; Jean S Marshall
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

9.  Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.

Authors:  Moshe Rogosnitzky; Esther Berkowitz; Alejandro R Jadad
Journal:  JMIR Public Health Surveill       Date:  2020-05-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.